tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Argent Biopharma Expands EU Presence with Key Milestones

Story Highlights
Argent Biopharma Expands EU Presence with Key Milestones

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Argent Biopharma ( (AU:RGT) ) has shared an update.

Argent Biopharma Ltd has achieved a significant milestone by commencing the formal supply of EU-GMP cannabinoid-based active pharmaceutical ingredients to the University Medical Centre Ljubljana for the treatment of drug-resistant epilepsy. This transition from pilot to routine hospital use marks a new commercial opportunity for the company in the EU market. Additionally, CannEpil® has gained approval for prescription in Germany, reinforcing Argent’s European expansion strategy and acceptance of cannabinoid-based medicine for CNS disorders. Strategic agreements with AusCann and David Trading Ltd further enhance Argent’s operational capabilities and market reach.

More about Argent Biopharma

Argent Biopharma Ltd is a company in the biopharmaceutical industry, focusing on cannabinoid-based therapies. Its primary products include CannEpil®, a cannabinoid-derived drug for refractory epilepsy. The company is actively involved in the European market, with a focus on expanding its presence and regulatory engagement in the EU and U.S.

Average Trading Volume: 39,751

Technical Sentiment Signal: Sell

Current Market Cap: A$4.82M

For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1